Cancer Cell Spread and Prognosis in Pancreatic Cancer
Author Information
Author(s): Gregory Sergeant, Tania Roskams, Jos van Pelt, François Houtmeyers, Raymond Aerts, Baki Topal
Primary Institution: University Hospital Leuven
Hypothesis
The study aims to evaluate the prognostic value of EpCAM detection in circulating tumor cells during the perioperative phase of pancreatic ductal adenocarcinoma.
Conclusion
Despite a significant increase in EpCAM counts in postoperative blood and peritoneal lavage fluid, this was not associated with worse prognosis after pancreatectomy for pancreatic ductal adenocarcinoma.
Supporting Evidence
- EpCAM positivity in blood increased from 25% preoperatively to 67.5% postoperatively.
- No significant associations were found between EpCAM positivity and cancer-specific or disease-free survival.
- The study is the first to use an EpCAM-based real-time RT-PCR assay in gastrointestinal cancer.
Takeaway
The study looked at how cancer cells spread during surgery for pancreatic cancer, but found that this spread doesn't mean the cancer will get worse.
Methodology
The study involved 48 patients with pancreatic ductal adenocarcinoma and 10 with chronic pancreatitis, using real-time RT-PCR to detect EpCAM in blood and peritoneal lavage samples.
Potential Biases
High background expression of EpCAM in chronic pancreatitis and healthy volunteers may affect specificity.
Limitations
The sample size is relatively small, which may lead to type I and II errors.
Participant Demographics
The study included 48 patients with pancreatic ductal adenocarcinoma (40 resectable, 8 unresectable) and 10 patients with chronic pancreatitis.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95%
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website